RGMP Share Price Performance
US$0
0.00 (0.00%)
Sorry, there is currently no price data for this company.
Regnum Corp. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
RGMP Community Narratives
There are no narratives available yet.
There are no community narratives available.
Snowflake Analysis
Regnum Corp. Key Details
About RGMP
- Founded
- 2016
- Employees
- 2
- CEO
- Website
Regnum Corp. develops and commercializes therapeutics that treat rare and infectious diseases. It develops Leronlimab (PRO 140), a monoclonal antibody C—C chemokine receptor type 5 antagonist, that is designed to prevent human immunodeficiency virus from entering human cells. The company was incorporated in 2016 and is based in New York, New York.
